Opthea (FRA:UKJ) Retained Earnings : €-679.60 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Opthea Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Opthea's retained earnings for the quarter that ended in Dec. 2024 was €-679.60 Mil.

Opthea's quarterly retained earnings declined from Dec. 2023 (€-417.83 Mil) to Jun. 2024 (€-538.55 Mil) and declined from Jun. 2024 (€-538.55 Mil) to Dec. 2024 (€-679.60 Mil).

Opthea's annual retained earnings declined from Jun. 2022 (€-205.23 Mil) to Jun. 2023 (€-331.78 Mil) and declined from Jun. 2023 (€-331.78 Mil) to Jun. 2024 (€-538.55 Mil).

Opthea Retained Earnings Historical Data

The historical data trend for Opthea's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Retained Earnings Chart

Opthea Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Retained Earnings

Get a 7-Day Free Trial

-69.96

-103.02

-205.23

-331.78

-538.55

Opthea Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Retained Earnings	Get a 7-Day Free Trial															-277.57	-331.78	-417.83	-538.55	-679.60

Opthea Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Opthea (FRA:UKJ) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Opthea Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (FRA:UKJ) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

OPT:USA OPT:Australia

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

Opthea Headlines

No Headlines